Author: Bernigaud, C.; Guillemot, D.; Ahmedâ€Belkacem, A.; Grimaldiâ€Bensouda, L.; Lespine, A.; Berry, F.; Softic, L.; Chenost, C.; Doâ€Pham, G.; Giraudeau, B.; Fourati, S.; Chosidow, O.
Title: Oral ivermectin for a scabies outbreak in a longâ€term care facility: potential value in preventing COVIDâ€19 and associated mortality Cord-id: q55my6yk Document date: 2021_3_1
ID: q55my6yk
Snippet: To-date, COVID-19 pandemic affected >85 million persons worldwide with 14% severe and 5% critical, and a general population case-fatality rate of 1%. Age is the main risk factor for severe disease and death1 making the long-term-care facilities (LTCFs) residents particularly vulnerable.2 COVID-19 therapeutic agents remain sparce and ivermectin, an antiparasitic showed anti-SARS-CoV-2 activity in vitro.3 Moxidectin, another macrocyclic lactone, with a longer plasma half-life, could be considered
Document: To-date, COVID-19 pandemic affected >85 million persons worldwide with 14% severe and 5% critical, and a general population case-fatality rate of 1%. Age is the main risk factor for severe disease and death1 making the long-term-care facilities (LTCFs) residents particularly vulnerable.2 COVID-19 therapeutic agents remain sparce and ivermectin, an antiparasitic showed anti-SARS-CoV-2 activity in vitro.3 Moxidectin, another macrocyclic lactone, with a longer plasma half-life, could be considered too.
Search related documents:
Co phrase search for related documents- long term care facility and ltcf resident: 1, 2
Co phrase search for related documents, hyperlinks ordered by date